{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:41:49Z","timestamp":1790264509686,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T00:00:00Z","timestamp":1471305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T00:00:00Z","timestamp":1471305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increasing evidence supports a role for abnormal immune activation and inflammatory responses in Huntington disease (HD). In this study, we evaluated the therapeutic potential of laquinimod (1 and 10\u2009mg\/kg), a novel immunomodulatory agent shown to be protective in a number of neuroinflammatory conditions, in the YAC128 mouse model of HD. Treatment with laquinimod for 6 months rescued atrophy in the striatum, in certain cortical regions, and in the corpus callosum of YAC128 HD mice. Diffusion tensor imaging showed that white matter microstructural abnormalities in the posterior corpus callosum were improved following treatment with low dose (1\u2009mg\/kg) laquinimod, and were paralleled by reduced levels of interleukin-6 in the periphery of YAC128 HD mice. Functionally, treatment with laquinimod (1 and 10\u2009mg\/kg) led to modest improvements in motor function and in depressive-like behaviour. Taken together, these results suggest that laquinimod may improve some features of pathology in HD, and provides support for the role of immune activation in the pathogenesis of HD.<\/jats:p>","DOI":"10.1038\/srep31652","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T10:25:19Z","timestamp":1471343119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Marta","family":"Garcia-Miralles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Juin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Vinh","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yanping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Franciosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Papapetropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Hayardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Pouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,16]]},"reference":[{"key":"BFsrep31652_CR1","doi-asserted-by":"crossref","unstructured":"Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 15005, 10.1038\/nrdp.2015.5 (2015).","DOI":"10.1038\/nrdp.2015.5"},{"key":"BFsrep31652_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet neurology 12, 637\u2013649 (2013).","journal-title":"Lancet neurology"},{"key":"BFsrep31652_CR3","doi-asserted-by":"crossref","unstructured":"Wild, E. J. & Tabrizi, S. J. Targets for future clinical trials in Huntington\u2019s disease: What\u2019s in the pipeline? Mov Disord, 10.1002\/mds.26007 (2014).","DOI":"10.1002\/mds.26007"},{"key":"BFsrep31652_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross, C. A. & Tabrizi, S. J. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet neurology 10, 83\u201398 (2011).","journal-title":"Lancet neurology"},{"key":"BFsrep31652_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti, A. & Glass, C. K. The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol 36, 364\u2013373 (2015).","journal-title":"Trends Immunol"},{"key":"BFsrep31652_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/mp.2011.28","volume":"16","author":"D Soulet","year":"2011","unstructured":"Soulet, D. & Cicchetti, F. The role of immunity in Huntington\u2019s disease. Mol Psychiatry 16, 889\u2013902 (2011).","journal-title":"Mol Psychiatry"},{"key":"BFsrep31652_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.coph.2015.09.008","volume":"26","author":"R Andre","year":"2015","unstructured":"Andre, R., Carty, L. & Tabrizi, S. J. Disruption of immune cell function by mutant huntingtin in Huntington\u2019s disease pathogenesis. Current opinion in pharmacology 26, 33\u201338 (2015).","journal-title":"Current opinion in pharmacology"},{"key":"BFsrep31652_CR8","doi-asserted-by":"publisher","first-page":"e0143563","DOI":"10.1371\/journal.pone.0143563","volume":"10","author":"A Labadorf","year":"2015","unstructured":"Labadorf, A. et al. RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. PLoS ONE 10, e0143563 (2015).","journal-title":"PLoS ONE"},{"key":"BFsrep31652_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp, E. et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60, 161\u2013172 (2001).","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFsrep31652_CR10","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai, Y. F. et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 130, 1759\u20131766 (2007).","journal-title":"Brain"},{"key":"BFsrep31652_CR11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","volume":"66","author":"N Pavese","year":"2006","unstructured":"Pavese, N. et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66, 1638\u20131643 (2006).","journal-title":"Neurology"},{"key":"BFsrep31652_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis, M. et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum Brain Mapp 32, 258\u2013270 (2011).","journal-title":"Hum Brain Mapp"},{"key":"BFsrep31652_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","volume":"83","author":"M Politis","year":"2015","unstructured":"Politis, M. et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers. Neurobiol. Dis. 83, 115\u2013121 (2015).","journal-title":"Neurobiol. Dis."},{"key":"BFsrep31652_CR14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist, M. et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 205, 1869\u20131877 (2008).","journal-title":"J Exp Med"},{"key":"BFsrep31652_CR15","doi-asserted-by":"publisher","first-page":"RRN1231","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild, E. et al. Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr 3, RRN1231 (2011).","journal-title":"PLoS Curr"},{"key":"BFsrep31652_CR16","doi-asserted-by":"crossref","unstructured":"Weiss, A. et al. Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Invest (2012), 10.1172\/JCI64565","DOI":"10.1172\/JCI64565"},{"key":"BFsrep31652_CR17","doi-asserted-by":"publisher","first-page":"RRN1205","DOI":"10.1371\/currents.RRN1205","volume":"2","author":"M Moscovitch-Lopatin","year":"2010","unstructured":"Moscovitch-Lopatin, M. et al. Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. PLoS Curr 2, RRN1205 (2010).","journal-title":"PLoS Curr"},{"key":"BFsrep31652_CR18","first-page":"388","volume":"73C","author":"U Tr\u00e4ger","year":"2014","unstructured":"Tr\u00e4ger, U. et al. Characterisation of immune cell function in fragment and full-length Huntington\u2019s disease mouse models. 73C, 388\u2013398 (2014).","journal-title":"Characterisation of immune cell function in fragment and full-length Huntington\u2019s disease mouse models."},{"key":"BFsrep31652_CR19","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1172\/JCI64484","volume":"122","author":"W Kwan","year":"2012","unstructured":"Kwan, W. et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest 122, 4737\u20134747 (2012).","journal-title":"J Clin Invest"},{"key":"BFsrep31652_CR20","doi-asserted-by":"crossref","unstructured":"Crotti, A. et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci, 10.1038\/nn.3668 (2014).","DOI":"10.1038\/nn.3668"},{"key":"BFsrep31652_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","volume":"32","author":"W Kwan","year":"2012","unstructured":"Kwan, W. et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington\u2019s disease. J Neurosci 32, 133\u2013142 (2012).","journal-title":"J Neurosci"},{"key":"BFsrep31652_CR22","doi-asserted-by":"publisher","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","volume":"32","author":"J Bouchard","year":"2012","unstructured":"Bouchard, J. et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease. J Neurosci 32, 18259\u201318268 (2012).","journal-title":"J Neurosci"},{"key":"BFsrep31652_CR23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2011.04.015","volume":"43","author":"A Khoshnan","year":"2011","unstructured":"Khoshnan, A. & Patterson, P. H. The role of I\u03baB kinase complex in the neurobiology of Huntington\u2019s disease. 43, 305\u2013311 (2011).","journal-title":"The role of I\u03baB kinase complex in the neurobiology of Huntington\u2019s disease."},{"key":"BFsrep31652_CR24","doi-asserted-by":"crossref","unstructured":"Tr\u00e4ger, U. et al. JAK\/STAT Signalling in Huntington\u2019s Disease Immune Cells. PLoS Curr 5 (2013).","DOI":"10.1371\/currents.hd.5791c897b5c3bebeed93b1d1da0c0648"},{"key":"BFsrep31652_CR25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1096\/fj.08-122275","volume":"23","author":"M D\u00edaz-Hern\u00e1ndez","year":"2009","unstructured":"D\u00edaz-Hern\u00e1ndez, M. et al. Altered P2X7-receptor level and function in mouse models of Huntington\u2019s disease and therapeutic efficacy of antagonist administration. FASEB J 23, 1893\u20131906 (2009).","journal-title":"FASEB J"},{"key":"BFsrep31652_CR26","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","volume":"22","author":"H-Y Hsiao","year":"2013","unstructured":"Hsiao, H.-Y., Chen, Y.-C., Chen, H.-M., Tu, P.-H. & Chern, Y. A critical role of astrocyte-mediated nuclear factor-\u03baB-dependent inflammation in Huntington\u2019s disease. Hum Mol Genet 22, 1826\u20131842 (2013).","journal-title":"Hum Mol Genet"},{"key":"BFsrep31652_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ana.24428","volume":"78","author":"H-Y Hsiao","year":"2015","unstructured":"Hsiao, H.-Y. et al. Aberrant astrocytes impair vascular reactivity in huntington\u2019s disease. Ann Neurol. 78, 178\u2013192 (2015).","journal-title":"Ann Neurol."},{"key":"BFsrep31652_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Tr\u00e4ger","year":"2014","unstructured":"Tr\u00e4ger, U. et al. HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF\u03baB pathway dysregulation. Brain 137, 819\u2013833 (2014).","journal-title":"Brain"},{"key":"BFsrep31652_CR29","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1523\/JNEUROSCI.2675-04.2004","volume":"24","author":"A Khoshnan","year":"2004","unstructured":"Khoshnan, A. et al. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 24, 7999\u20138008 (2004).","journal-title":"J Neurosci"},{"key":"BFsrep31652_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2014.04.002","volume":"262PA","author":"M Varrin-Doyer","year":"2014","unstructured":"Varrin-Doyer, M., Zamvil, S. S. & Schulze-Topphoff, U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Experimental Neurology 262PA, 66\u201371 (2014).","journal-title":"Experimental Neurology"},{"key":"BFsrep31652_CR31","doi-asserted-by":"crossref","unstructured":"Br\u00fcck, W. et al. Reduced astrocytic NF-\u03baB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol, 10.1007\/s00401-012-1009-1 (2012).","DOI":"10.1007\/s00401-012-1009-1"},{"key":"BFsrep31652_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2012.06.005","volume":"251","author":"R Aharoni","year":"2012","unstructured":"Aharoni, R. et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 251, 14\u201324 (2012).","journal-title":"J Neuroimmunol"},{"key":"BFsrep31652_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajpath.2011.09.037","volume":"180","author":"J Th\u00f6ne","year":"2012","unstructured":"Th\u00f6ne, J. et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180, 267\u2013274 (2012).","journal-title":"Am J Pathol"},{"key":"BFsrep31652_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","volume":"81","author":"C Zuccato","year":"2007","unstructured":"Zuccato, C. & Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington\u2019s disease. Prog Neurobiol 81, 294\u2013330 (2007).","journal-title":"Prog Neurobiol"},{"key":"BFsrep31652_CR35","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","volume":"12","author":"EJ Slow","year":"2003","unstructured":"Slow, E. J. et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12, 1555\u20131567 (2003).","journal-title":"Hum Mol Genet"},{"key":"BFsrep31652_CR36","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1109\/TIP.2011.2126587","volume":"20","author":"N Chou","year":"2011","unstructured":"Chou, N., Wu, J., Bai Bingren, J., Qiu, A. & Chuang, K.-H. Robust automatic rodent brain extraction using 3-D pulse-coupled neural networks (PCNN). IEEE Trans Image Process 20, 2554\u20132564 (2011).","journal-title":"IEEE Trans Image Process"},{"key":"BFsrep31652_CR37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.mri.2015.06.010","volume":"33","author":"X Hong","year":"2015","unstructured":"Hong, X., To, X. V., Teh, I., Soh, J. R. & Chuang, K.-H. Evaluation of EPI distortion correction methods for quantitative MRI of the brain at high magnetic field. Magn Reson Imaging 33, 1098\u20131105 (2015).","journal-title":"Magn Reson Imaging"},{"key":"BFsrep31652_CR38","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S1053-8119(03)00336-7","volume":"20","author":"JLR Andersson","year":"2003","unstructured":"Andersson, J. L. R., Skare, S. & Ashburner, J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage 20, 870\u2013888 (2003).","journal-title":"Neuroimage"},{"key":"BFsrep31652_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/jmrb.1994.1037","volume":"103","author":"PJ Basser","year":"1994","unstructured":"Basser, P. J., Mattiello, J. & LeBihan, D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B 103, 247\u2013254 (1994).","journal-title":"J Magn Reson B"},{"key":"BFsrep31652_CR40","unstructured":"Penny, W. D., Friston, K. J., Ashburner, J. T. & Kiebel, S. J. Statistical parametric mapping: the analysis of functional brain images: the analysis of functional brain images. (2011)."},{"key":"BFsrep31652_CR41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/brain\/awp006","volume":"132","author":"MA Pouladi","year":"2009","unstructured":"Pouladi, M. A. et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132, 919\u2013932 (2009).","journal-title":"Brain"},{"key":"BFsrep31652_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.nbd.2011.03.018","volume":"43","author":"JB Carroll","year":"2011","unstructured":"Carroll, J. B. et al. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol. Dis. 43, 257\u2013265 (2011).","journal-title":"Neurobiol. Dis."},{"key":"BFsrep31652_CR43","doi-asserted-by":"crossref","unstructured":"Teo, R. T. Y. et al. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Hum Mol Genet ddw122, 10.1093\/hmg\/ddw122 (2016).","DOI":"10.1093\/hmg\/ddw122"},{"key":"BFsrep31652_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","volume":"76","author":"AL Southwell","year":"2015","unstructured":"Southwell, A. L. et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 76, 46\u201356 (2015).","journal-title":"Neurobiol. Dis."},{"key":"BFsrep31652_CR45","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/hmg\/dds037","volume":"21","author":"MA Pouladi","year":"2012","unstructured":"Pouladi, M. A. et al. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 21, 2219\u20132232 (2012).","journal-title":"Hum Mol Genet"},{"key":"BFsrep31652_CR46","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","volume":"25","author":"JM Van Raamsdonk","year":"2005","unstructured":"Van Raamsdonk, J. M. et al. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington\u2019s disease. J Neurosci 25, 4169\u20134180 (2005).","journal-title":"J Neurosci"},{"key":"BFsrep31652_CR47","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/nm.2056","volume":"15","author":"S-I Okamoto","year":"2009","unstructured":"Okamoto, S.-I. et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15, 1407\u20131413 (2009).","journal-title":"Nat Med"},{"key":"BFsrep31652_CR48","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","volume":"65","author":"AJ Milnerwood","year":"2010","unstructured":"Milnerwood, A. J. et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice. Neuron 65, 178\u2013190 (2010).","journal-title":"Neuron"},{"key":"BFsrep31652_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.nbd.2012.06.026","volume":"48","author":"MA Pouladi","year":"2012","unstructured":"Pouladi, M. A. et al. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 48, 282\u2013289 (2012).","journal-title":"Neurobiol. Dis."},{"key":"BFsrep31652_CR50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nbd.2014.12.030","volume":"76","author":"BKY Wong","year":"2015","unstructured":"Wong, B. K. Y. et al. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiol. Dis. 76, 24\u201336 (2015).","journal-title":"Neurobiol. Dis."},{"key":"BFsrep31652_CR51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/hmg\/ddl072","volume":"15","author":"JM Van Raamsdonk","year":"2006","unstructured":"Van Raamsdonk, J. M. et al. Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet 15, 1513\u20131523 (2006).","journal-title":"Hum Mol Genet"},{"key":"BFsrep31652_CR52","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/hmg\/ddq026","volume":"19","author":"MA Pouladi","year":"2010","unstructured":"Pouladi, M. A. et al. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 19, 1528\u20131538 (2010).","journal-title":"Hum Mol Genet"},{"key":"BFsrep31652_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jnc.13553","volume":"137","author":"L Dobson","year":"2016","unstructured":"Dobson, L. et al. Laquinimod dampens hyperactive cytokine production in Huntington\u2019s disease patient myeloid cells. J Neurochem 137, 782\u2013794 (2016).","journal-title":"J Neurochem"},{"key":"BFsrep31652_CR54","doi-asserted-by":"publisher","first-page":"e33797","DOI":"10.1371\/journal.pone.0033797","volume":"7","author":"U Schulze-Topphoff","year":"2012","unstructured":"Schulze-Topphoff, U. et al. Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity. PLoS ONE 7, e33797 (2012).","journal-title":"PLoS ONE"},{"key":"BFsrep31652_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jneuroim.2010.07.009","volume":"227","author":"C Wegner","year":"2010","unstructured":"Wegner, C. et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227, 133\u2013143 (2010).","journal-title":"J Neuroimmunol"},{"key":"BFsrep31652_CR56","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/1352458512469698","volume":"19","author":"F Ruffini","year":"2013","unstructured":"Ruffini, F. et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult. Scler. 19, 1084\u20131094 (2013).","journal-title":"Mult. Scler."},{"key":"BFsrep31652_CR57","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/brb3.174","volume":"3","author":"S Moore","year":"2013","unstructured":"Moore, S. et al. Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav 3, 664\u2013682 (2013).","journal-title":"Brain Behav"},{"key":"BFsrep31652_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acn3.67","volume":"1","author":"MK Mishra","year":"2014","unstructured":"Mishra, M. K. et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Annals of Clinical and Translational Neurology 1, 409\u2013422 (2014).","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"BFsrep31652_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jneuroim.2014.06.012","volume":"274","author":"K Pitarokoili","year":"2014","unstructured":"Pitarokoili, K. et al. Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. J Neuroimmunol 274, 38\u201345 (2014).","journal-title":"J Neuroimmunol"},{"key":"BFsrep31652_CR60","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0028-3908(02)00015-1","volume":"42","author":"L-P Zou","year":"2002","unstructured":"Zou, L.-P. et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1\/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42, 731\u2013739 (2002).","journal-title":"Neuropharmacology"},{"key":"BFsrep31652_CR61","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/art.38259","volume":"66","author":"EV Louren\u00e7o","year":"2014","unstructured":"Louren\u00e7o, E. V., Wong, M., Hahn, B. H., Palma-Diaz, M. F. & Skaggs, B. J. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol 66, 674\u2013685 (2014).","journal-title":"Arthritis Rheumatol"},{"key":"BFsrep31652_CR62","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12031-014-0387-3","volume":"55","author":"I Gil-Ad","year":"2015","unstructured":"Gil-Ad, I. et al. Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models. J Mol Neurosci 55, 552\u2013560 (2015).","journal-title":"J Mol Neurosci"},{"key":"BFsrep31652_CR63","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nbd.2014.12.009","volume":"74","author":"GR Poudel","year":"2015","unstructured":"Poudel, G. R. et al. Longitudinal change in white matter microstructure in Huntington\u2019s disease: The IMAGE-HD study. Neurobiol. Dis. 74, 406\u2013412 (2015).","journal-title":"Neurobiol. Dis."},{"key":"BFsrep31652_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/JHD-150160","volume":"4","author":"S Gregory","year":"2015","unstructured":"Gregory, S. et al. Neuropsychiatry and White Matter Microstructure in Huntington\u2019s Disease. Journal of Huntington\u2019s Disease 4, 239\u2013249 (2015).","journal-title":"Journal of Huntington\u2019s Disease"},{"key":"BFsrep31652_CR65","doi-asserted-by":"publisher","first-page":"11758","DOI":"10.1038\/ncomms11758","volume":"7","author":"A Benraiss","year":"2016","unstructured":"Benraiss, A. et al. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun 7, 11758 (2016).","journal-title":"Nat Commun"},{"key":"BFsrep31652_CR66","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.neuroimage.2011.08.043","volume":"59","author":"C Metzler-Baddeley","year":"2012","unstructured":"Metzler-Baddeley, C., O\u2019Sullivan, M. J., Bells, S., Pasternak, O. & Jones, D. K. How and how not to correct for CSF-contamination in diffusion MRI. Neuroimage 59, 1394\u20131403 (2012).","journal-title":"Neuroimage"},{"key":"BFsrep31652_CR67","doi-asserted-by":"crossref","unstructured":"Sepers, M. D. & Raymond, L. A. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington\u2019s disease. Drug Discov Today, 10.1016\/j.drudis.2014.02.006 (2014).","DOI":"10.1016\/j.drudis.2014.02.006"},{"key":"BFsrep31652_CR68","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","volume":"90","author":"R Schwarcz","year":"2010","unstructured":"Schwarcz, R., Guidetti, P., Sathyasaikumar, K. & Muchowski, P. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington\u2019s disease. Prog Neurobiol 90, 230\u2013245 (2010).","journal-title":"Prog Neurobiol"},{"key":"BFsrep31652_CR69","first-page":"25","volume":"74C","author":"Y Miki","year":"2014","unstructured":"Miki, Y., Tanji, K., Mori, F. & Wakabayashi, K. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington\u2019s disease. 74C, 25\u201331 (2014).","journal-title":"receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington\u2019s disease."},{"key":"BFsrep31652_CR70","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1038\/cddis.2013.170","volume":"4","author":"A Hyrskyluoto","year":"2013","unstructured":"Hyrskyluoto, A. et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-\u03baB pathway. Cell Death Dis 4, e646 (2013).","journal-title":"Cell Death Dis"},{"key":"BFsrep31652_CR71","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.coph.2006.08.014","volume":"7","author":"ALO Hebb","year":"2007","unstructured":"Hebb, A. L. O. & Robertson, H. A. Role of phosphodiesterases in neurological and psychiatric disease. Current opinion in pharmacology 7, 86\u201392 (2007).","journal-title":"Current opinion in pharmacology"},{"key":"BFsrep31652_CR72","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s12035-014-8974-4","volume":"52","author":"J Ooi","year":"2015","unstructured":"Ooi, J., Hayden, M. R. & Pouladi, M. A. Inhibition of Excessive Monoamine Oxidase A\/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Mol Neurobiol 52, 1850\u20131861 (2015).","journal-title":"Mol Neurobiol"},{"key":"BFsrep31652_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.expneurol.2016.01.019","volume":"278","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles, M. et al. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental Neurology 278, 4\u201310 (2016).","journal-title":"Experimental Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep31652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31652","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep31652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:43:59Z","timestamp":1672897439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep31652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,16]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,30]]}},"alternative-id":["BFsrep31652"],"URL":"https:\/\/doi.org\/10.1038\/srep31652","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,16]]},"assertion":[{"value":"3 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yes, there is potential competing interest. L. H., S. P. and M. R. H. are employees of Teva Pharmaceuticals. Teva Pharmaceuticals played no role in the treatment or testing of animals, or the collection, analysis and interpretation of the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31652"}}